[How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Condition de réalisation de la cytaphérèse pour la mise à disposition du matériel biologique nécessaire à la production de CAR T-cells commerciaux : avis d’experts proposé par la SFGM-TC.
Adolescent
Antigens, CD19
/ therapeutic use
Biological Products
Child
Commerce
Consensus
Genetic Engineering
/ methods
Humans
Immunotherapy, Adoptive
Leukapheresis
/ methods
Leukemia, B-Cell
/ therapy
Lymphoma, Large B-Cell, Diffuse
/ therapy
Mediastinal Neoplasms
/ therapy
Receptors, Antigen, T-Cell
/ therapeutic use
T-Lymphocytes
Tissue and Organ Harvesting
/ methods
Young Adult
B-cell acute lymphoblastic leukemia
CAR T-cells
Cytapheresis
Cytaphérèse
Diffuse large B-cell lymphoma
Leucémie aiguë lymphoblastique B
Lymphome diffus à grandes cellules B
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
05
09
2020
revised:
05
11
2020
accepted:
09
11
2020
pubmed:
22
2
2021
medline:
7
4
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present at the surface of malignant cells. In Europe, tisagenlecleucel (Kymriah™) has a marketing authorization for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and young adults and for the relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta™) is the treatment of relapsed/refractory DLBCL and mediastinal B-cell lymphoma. Both products are "living drugs" and genetically modified autologous T cells directed against CD19 which is an antigen expressed throughout B lymphoid differentiation and on many B malignancies. This collaborative work - part of a series of expert works on the topic - aims to provide practical advice to assist collection facilities that procure the starting material i.e. blood mononuclear cells for autologous CAR T-cell manufacturing.
Identifiants
pubmed: 33610284
pii: S0007-4551(21)00036-9
doi: 10.1016/j.bulcan.2020.11.014
pii:
doi:
Substances chimiques
Antigens, CD19
0
Biological Products
0
Receptors, Antigen, T-Cell
0
tisagenlecleucel
Q6C9WHR03O
axicabtagene ciloleucel
U2I8T43Y7R
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
295-303Informations de copyright
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.